A Conceptual Design of a Novel Multi-Hexagonal Beta Applicator Intended to Treat Non-Melanoma Skin Cancers

Article Sidebar

PDF
Published: Oct 30, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i10-72
Keywords:
beta radiation, Yttrium-90, dose distributions, multi-hexagonal beta applicator, brachytherapy, non-melanoma skin cancer

Main Article Content

Eduardo De Paiva
Division of Medical Physics, Institute of Radiation Protection and Dosimetry Rio de Janeiro, Brazil

Abstract

Due to its short range in tissue and high dose gradient beta radiation may be used to the therapy of small and superficial skin lesions. In this short study a conceptual design of a novel multi-hexagonal beta applicator loaded with Yttrium-90 is presented. Calculations of dose rates around the applicator area performed using the beta-point source dose function formalism and initial results show that over 90\% of the beta radiation energy from the multi-hexagonal applicator loaded with Yttrium-90 is absorbed in the first layers of the skin tissue. Results show that the multi-hexagonal beta applicator has the potential to be used in the brachytherapy treatment of non-melanoma skin cancers.

Article Details

How to Cite
De Paiva, E. (2023). A Conceptual Design of a Novel Multi-Hexagonal Beta Applicator Intended to Treat Non-Melanoma Skin Cancers. International Journal of Medical Science and Clinical Research Studies, 3(10), 2507–2513. https://doi.org/10.47191/ijmscrs/v3-i10-72
Issue
Vol. 3 No. 10 (2023): Volume 03 Issue 10 October 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: A population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clinic Proceedings 2017; 92: 890-898.

II. Ferry AM, Sarrami, SM, Hollier PC, Thornton JF. Treatment of non-melanoma skin cancers in the absence of Mohs microsurgery. Plastic and Reconstructive Surgery - Global open 2020; 8: e3300.

III. Pashazadeh A, Castro N, Morganti E, et al. Conceptual design of a personalized radiation therapy patch for skin cancer. Current Directions in Biomedical Engineering 2018; 4: 607-610.

IV. Chmura J, Erdman A, Ehler E, et al. Novel design and development of a 3D printed conformal superficial brachytherapy device for the treatment of non-melanoma skin cancer and keloids. 3D Printing in Medicine 2019; 5: 1-6.

V. Pashazadeh A, Landes R, Boese A, et al. Superficial skin cancer therapy with Y-90 microspheres: A feasibility study on patch preparation. Skin Research and Technology 2020; 26: 25-29.

VI. Pashazadeh A, Robatjazi M, Castro NJ, Friebe M. A multiwell applicator for conformal brachytherapy of superficial skin tumors: A simulation study. Skin Research and Technology 2020; 26: 537-541.

VII. Pashazadeh A, De Paiva E, Mahmoodiana N, Friebe M. Calculation of beta radiation dose of a circular Y-90 skin patch: Analytical and simulation methods. Radiation Physics and Chemistry 2020; 166: 108491.

VIII. Rogers B, Lawrence J, Chmra J, et al. Dosimetric characterization of a novel 90Y source for use in the conformal superficial brachytherapy device. Physica Medica 2020; 72: 52-59.

IX. De Paiva E, Pashazadeh A, Robatjazi M. Calculations of beta radiation doses from multiwell Phosphorus-32 and Yttrium-90 applicators designed to be used in the treatment of superficial skin tumors: comparison of Monte Carlo and analytical methods. The European Physical Journal Plus 2022; 137: 916.

X. Yosefof E, Kurman N, and Yaniv D. The role of radiation therapy in the treatment of non-melanoma skin cancer. Cancers 2023; 15: 2408.

XI. De Paiva E. Role of the use of conformal beta applicators in the radiation treatment of small skin lesions. Radiology and Imaging Journal 2023; 2: 1-3.

XII. De Paiva E. A conceptual design of a novel hexagonal beta applicator intended to be used in the treatment of non-melanoma skin cancers. European Chemical Bulletin 2023; 12: 9307-9317.

XIII. McMahon JM. The long-term effect of experimental beta-radiation therapy on the human cornea. Contact Lens and Anterior Eye 2017; 30(4): 249-253.

XIV. Klaassen NJM, Arntz MJ, Arranja AG, et al. The various therapeutic applications of the medical isotope holmium-166: a narrative review. EJNMMI Radiopharmacy and Chemistry 2019; 4: 19.

XV. De Paiva E. Estimates of relative beta radiation doses on central and lateral axes of ruthenium/rhodium COB-type plaque used in eye brachytherapy. Applied Radiation and Isotopes 2020; 156: 108991.

XVI. Radhoe SP, Schuurman AS, Ligthart JM, et al. Two decades after coronary radiation therapy: A single center longitudinal clinical study. Catheterization and Cardiovascular Interventions 2020; 96(3): E204-E212.

XVII. Arora S, Stea BD, Hamilton RJ, Chhablani J. Brachytherapy for Central Serous Chorioretinopathy. Ophthalmology and Therapy 2022; 5: 1611-1616.

XVIII. Diaz MJ, Kwak SH, Root KT, et al. Current Approaches to Craniopharyngioma Management. Frontiers in Bioscience 2022; 27(12): 328.

XIX. Kunikowska J, Morgenstern A, Pelka K, et al. Targeted alpha therapy for glioblastoma. Frontiers in Medicine 2022; 9: 1085245.

XX. Loevinger R. The dosimetry of beta sources in tissue. The point-source function. Radiology 1956; 66: 55-62.

XXI. Vynckier S, Wambersie A. Dosimetry of beta sources in radiotherapy. I. The beta point source dose function. Physics in Medicine and Biology 1982; 27: 1339-1347.

XXII. Vynckier S, Wambersie A. Dosimetry of beta sources in radiotherapy: absorbed dose distributions around plane sources. Radiation Protection. Dosimetry 1986; 14: 169-173.